- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00717184
A Pilot Study of Autologous Ex Vivo Activated NK Cell Infusion in the Treatment of Metastatic Nasopharyngeal Carcinoma
- To demonstrate the feasibility of leukapheresis and ex vivo activation of autologous NK cells in patients with metastatic NPC
- To demonstrate the safety of low dose systemic IL-2 in combination with escalating doses of autologous Ex Vivo Activated NK cells in patients with metastatic NPC
- To assess immune measurements such as quantitation of regulatory T cells, EBV specific T cells, serum cytokine levels, and NK cell function after treatment with IL-2 and autologous Ex Vivo Activated NK cells
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
We are investigating the use of immune cell therapy in metastatic Nasopharyngeal Cancer (NPC). Recent small studies have shown that EBV specific cytotoxic T cells can be infused into NPC patients with some good clinical effect including tumor responses. We are trying to achieve a similar result using a less complex and less costly approach, with Natural Killer (NK) cells. NK cells are known to recognize tumor and virally infected cells through a variety of mechanisms. Also, NK cells influence the development of antigen-specific T cell responses via reciprocal interactions with dendritic cells and the secretion of IFNγ.
This is a pilot clinical trial to study the feasibility of collecting, manipulating , and infusing autologous enriched NK cells activated by short-term incubation in IL-2. Leukapheresis units will be collected from eligible patients with NPC. NK cells will be selected and activated with IL-2 prior to re-infusion. Patients will receive low dose IL-2 after infusion of activated NK cells. Post infusion monitoring will include peripheral blood T cell subsets, cytokine secretion and serum cytokine levels. The parameters will be correlated to clinical observations. If clinical efficacy is shown, our protocol could represent a simple way of harnessing the immune system of the patient for treatment of this disease. This study will also serve as platform technology development for later trials involving manipulating cell therapy products.
Study Type
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Singapore, Singapore
- National University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Biopsy proven, metastatic nasopharyngeal carcinoma (NPC) (WHO grade III) and measurable metastatic disease.
- ECOG performance status <2.
- Life expectancy greater than 6 months.
- Patient must have adequate access for leukapheresis (vein or central line)
Patients must have normal organ and marrow function as defined below:
- leukocytes >3,500/μl, absolute neutrophil count >1,500/μl, platelets >100,000/μl.
- Organ function tests:
- total bilirubin <1.5X normal, AST(SGOT) / ALT(SGPT) <2.5 X of normal or <5X in the case of patients with liver metastases;
- creatinine <1.5X normal institutional limits or a calculated creatinine clearance of > 50 mls/min.
- Negative pregnancy test within 4 weeks of enrollment in women of child-bearing age.
- Patients with fertility/child bearing potential must agree to avoid pregnancy.
- Age 18 and older
- Patients must have received at least one prior systemic treatments for "metastatic nasopharyngeal carcinoma".Neoadjuvant chemotherapy or concurrent chemoradiation administered for localized disease does is not considered a line of prior treatment.
- Patient's last dose of systemic chemotherapy must have been given at least 4 weeks prior to the beginning of study treatment. Local radiation therapy will be allowed only if there are other sites of measurable disease.
- Patients must have at least one site of measurable disease. Sites of measurable disease which has been irradiated can be used if greater than 60 days has passed between the completion of radiation treatment and the start of NK cell treatment.
Exclusion Criteria:
- Patients with active infections requiring oral or intravenous antibiotics are not eligible for entry onto the study until resolution of the infection.
- History of HIV infection, chronic active Hepatitis B or C.
- Patients with prior or currently active autoimmune disease requiring management with systemic immunosuppression are not eligible. Asthma or chronic obstructive pulmonary disease that does not require daily systemic corticosteroids is acceptable.
- Enrollment on another experimental treatment within 28 days of starting treatment on this study.
- Systemic steroids within 28 days of starting study treatment.
- Uncontrolled medical problems.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Masking: None (Open Label)
Collaborators and Investigators
Investigators
- Principal Investigator: Alvin Seng Cheong Wong, MBBS, MRCP, National University Hospital, Singapore
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Pharyngeal Neoplasms
- Otorhinolaryngologic Neoplasms
- Head and Neck Neoplasms
- Nasopharyngeal Diseases
- Pharyngeal Diseases
- Stomatognathic Diseases
- Otorhinolaryngologic Diseases
- Nasopharyngeal Neoplasms
- Nasopharyngeal Carcinoma
Other Study ID Numbers
- NP01/02/06
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Nasopharyngeal
-
National Cancer Institute (NCI)NRG OncologyTerminatedRecurrent Nasopharyngeal Carcinoma | Stage IV Nasopharyngeal Carcinoma AJCC v8 | Metastatic Nasopharyngeal Carcinoma | Metastatic Nasopharyngeal Keratinizing Squamous Cell Carcinoma | Metastatic Nasopharyngeal Nonkeratinizing Carcinoma | Metastatic Nasopharyngeal Undifferentiated Carcinoma | Nasopharyngeal... and other conditionsUnited States, Canada, China, Singapore
-
Cancer Institute and Hospital, Chinese Academy...RecruitingMetastatic Nasopharyngeal CancerChina
-
National Cancer Centre, SingaporeNovartis; Advanced Accelerator ApplicationsRecruitingMetastatic Nasopharyngeal CancerSingapore
-
Fuda Cancer Hospital, GuangzhouShenzhen Hank Bioengineering InstituteCompletedMetastatic Nasopharyngeal CancerChina
-
Alliance for Clinical Trials in OncologyNot yet recruitingRecurrent Nasopharyngeal Carcinoma | Stage IV Nasopharyngeal Carcinoma AJCC v8 | Metastatic Nasopharyngeal Carcinoma
-
Cancer Institute and Hospital, Chinese Academy...RecruitingRecurrent Nasopharyngeal Carcinoma | Metastatic Nasopharyngeal CarcinomaChina
-
Affiliated Cancer Hospital & Institute of Guangzhou...Hunan Cancer Hospital; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNot yet recruitingMetastatic Nasopharyngeal Carcinoma
-
XIANG YANQUNActive, not recruitingChemotherapy Effect | Metastatic Nasopharyngeal CarcinomaChina
-
Jiangsu HengRui Medicine Co., Ltd.Sun Yat-sen UniversityCompletedRecurrent Nasopharyngeal Carcinoma | Metastatic Nasopharyngeal CarcinomaChina
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingRecurrent / Metastatic Nasopharyngeal CancerChina
Clinical Trials on Interleukin, NK cells
-
Dana-Farber Cancer InstituteImmunityBio, Inc.; Kidney Cancer AssociationNot yet recruitingRenal Cell Carcinoma | Urothelial Carcinoma | Renal CarcinomaUnited States
-
Chongqing Public Health Medical CenterZhejiang Qixin Biotech; Chongqing Sidemu BiotechUnknown
-
Asclepius Technology Company Group (Suzhou) Co....UnknownPancreatic CancerChina
-
Hangzhou Cheetah Cell Therapeutics Co., LtdTerminatedSafety and EfficacyChina
-
Asclepius Technology Company Group (Suzhou) Co....UnknownMalignant TumorChina
-
Xinxiang medical universityFirst Affiliated Hospital of Xinjiang Medical UniversityCompleted
-
jiuwei cuiUnknownSmall Cell Lung CancerChina
-
Nationwide Children's HospitalNot yet recruitingHigh Grade GliomaUnited States
-
Instituto de Investigación Hospital Universitario...Recruiting
-
The Second Affiliated Hospital of Fujian Medical...Shanghai iCELL Biotechnology Co., Ltd, Shanghai, ChinaUnknown